RT Journal Article
SR Electronic
A1 Jacobson, Anne
T1 Irbesartan Fails to Prevent Most Vascular Events in Patients with AF
JF MD Conference Express
YR 2009
FD SAGE Publications
VO 9
IS 4
SP 12
OP 13
DO 10.1177/155989770904005
UL http://mdc.sagepub.com/content/9/4/12.2.abstract
AB In the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events [ACTIVE-I; NCT00249795], treatment with irbesartan failed to lower the risk of stroke, myocardial infarction, and vascular death compared with placebo in patients with atrial fibrillation (AF). However, irbesartan may have a role in preventing heart failure, recurrent embolic events, and cardiovascular hospitalizations in patients with AF.